2017 American Transplant Congress
Desensitization Regimen for the Patients with High Isoagglutinin Titers to Undergo Adult ABO-Incompatible Living Donor Liver Transplantation.
Liver and Transplantation Surgery, Chang-Gung Memorial Hospital, Taoyuan, Taiwan
Background: Adult living donor liver transplantation can be performed across ABO blood type barrier successfully by depleting B cells using rituximab. However, the patients with…2017 American Transplant Congress
CXCL13 as a New Systemic Biomarker for B-Cell Involvement in Acute Kidney Allograft Rejection.
The majority of kidney allograft rejections are T cell mediated (TCMR). However, it has been shown that in the presence of B-cell clusters the course…2017 American Transplant Congress
The Effect of Histological Isolated Endarteritis and Solid Endoarteritis Combined with CD20 Positive B Cell Infiltration Appeared in Acute Cellular Rejection on Kidney Allograft Survival.
BackgroundEndarteritis post renal transplantation is regarded as T-cell mediated acute rejection by Banff classification. Recently, results from DNA microarrays suggested that endovasculitis did not represent…2016 American Transplant Congress
Prospective Long-Term Analysis of B- and Plasma Cell Subsets in Renal Transplant Patients After Combined Treatment with Rituximab and Bortezomib in Antibody Mediated Rejection.
Nephrology, Charité Berlin, Berlin, Germany.
Treatment of antibody-mediated rejection (AMR) in renal transplant (Tx) patients (pts) is still challenging and long-term outcome remain poor. Our present treatment strategy with bortezomib…2016 American Transplant Congress
Absence of Acute Allograft Rejection in the Early Post Operative Period in a Full Face VCA Recipient with a Positive B-Cell Flow Cytometric Crossmatch Utilizing an Induction Immunosuppression Regimen Including Anti-thymocyte and Anti-CD20 Agents.
Background: The presence of donor-specific antibodies (DSA) to human leukocyte antigen (HLA) convey increased risk of allograft rejection. Patients suffering full-thickness burns to the face…2016 American Transplant Congress
Reduced Incidence of Rejection in AB0-incompatible Kidney Transplantation – Five Year Follow-Up in a Single Center.
Nephrology and Hypertension, Universitaet Erlangen-Nuernberg, Erlangen, Germany.
Introduction:Living kidney donation is the method of choice to expand the donor pool in times of severe organ shortage. In many centers, AB0-incompatible kidney transplantation…2016 American Transplant Congress
First Experience with Obinutuzumab (Type II Anti-CD20) in Patients with Treatment-Resistant Glomerular Diseases and Antibody-Mediated Rejection.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: There is extensive experience with rituximab (RTX,Type I anti-CD20) for desensitization (DES) and treatment of ABMR. There is also a comparable experience in treatment…2016 American Transplant Congress
Long-Term Assessment of the Safety and Efficacy of IVIG and Rituximab-Based Desensitization (DES).
Comprehensive Transplantation Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: HLA sensitized patients constitute a growing number of ESRD patients with an immunologic barrier to successful transplantation. Desensitization (DES) therapies have emerged to address…2016 American Transplant Congress
Rituximab Induction in Cardiac Transplantation Is Associated with Accelerated Coronary Artery Vasculopathy: CTOT11.
On Behalf of the CTOT11 Consortium, Brigham & Women's Hospital, Boston, MA.
PurposeThe NIH-funded study CTOT11: Prevention of Cardiac Allograft Vasculopathy Using Rituximab (RIT) Therapy in Cardiac Transplantation, was a randomized clinical trial in non-sensitized primary heart…2015 American Transplant Congress
Long-Term Excellent Results of ABO-Incompatible Kidney Transplantations at Multicenter Japanese Case Series
[Background]Although kidney transplantation (KT) is the most reassuring treatment for patients with ESRD, shortage of organ donation in Japan is crucial. This issue has forced…